Clinical Trials Browser

Hematologic Neoplasms × Nivolumab × Clear all

NCT03816345 2026-03-18

Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer

Arthritis, Rheumatoid, Autoimmune Diseases, Colitis, Ulcerative, Crohn Disease, Dermatomyositis, Lupus Erythematosus, Systemic, Multiple Sclerosis, Psoriasis, Scleroderma, Systemic, Sjogren's Syndrome, Inflammatory Bowel Diseases, Arthritis, Psoriatic, Hematologic Neoplasms

NCT02329847 2025-05-25

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies

Phase 1/2 Completed

144 enrolled 22 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT04781855 2025-02-28

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Phase 1 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03436862 2023-12-05

Nivolumab Maintenance Therapy After Autologous Stem Cell Transplant in Hodgkin Lymphoma Pts at Relapse/Progression Risk

Phase 2 Completed

37 enrolled 6 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Hematologic Neoplasms

NCT03121534 2023-02-17

Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation

Phase 2 Terminated

9 enrolled 10 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT03146468 2021-09-23

NIVALLO

Phase 2 Unknown

14 enrolled

Other hematologic neoplasm

Hematologic Neoplasms

NCT01822509 2021-06-24

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Phase 1 Completed

71 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04439214 2021-04-06

Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)

Phase 2 Completed

47 enrolled 10 charts

LymphoidOther hematologic neoplasmPlasma cell

Turcot syndrome, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT02985554 2020-06-25

Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies

Phase 1 Terminated

3 enrolled

Other hematologic neoplasm

Hematologic Neoplasms